Methods| Under statutory authority pursuant to public health, no approval from institutional
review boards or informed consent was required for this case series analysis. We reviewed …

Discussion Daratumumab is an IgG1κ monoclonal antibody approved by the United States
Food and Drug Administration for the treatment of multiple myeloma as both monotherapy …

Daratumumab is an anti-CD38 monoclonal antibody approved for use in multiple myeloma
in 2015 and under investigation for use in light-chain amyloidosis. We report a case of a …

Daratumumab-containing regimens are an effective treatment for advanced cases of
multiple myeloma. Overall, daratumumab has a favourable safety profile, although rare side …

Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for
recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) …

Discussion Specific ophthalmic toxicity is a relatively new observation in relation to myeloma
treatment. However, it is described as an important adverse event associated with new …

Daratumumab-based therapy has been shown to have significant clinical efficacy in phase 3
trials of patients with relapse or refractory multiple myeloma. Outside of clinical trials …

Background: Daratumumab is an anti-CD38 antibody with efficacy both in relapsed and
newly diagnosed multiple myeloma (NDMM). Clinical trials evaluating daratumumab have …

Introduction Daratumumab is an anti-CD38 monoclonal antibody widely used for treating
patients with newly diagnosed or relapsed/refractory multiple myeloma. The subcutaneous …

Dear Editor, Daratumumab is a first-in-class human IgG1 kappa CD38-targeted monoclonal
antibody that has become a critical component in the treatment of newly diagnosed multiple …